News
December 2019
“Pulse Biosciences, Inc. presented results of three clinical studies demonstrating high clearance rates across its benign skin lesion portfolio during the ASDS 2019 Annual Meeting in Chicago. The company’s proprietary CellFX System harnessing Nano-Pulse Stimulation (NPS) technology is under FDA review for the management of Sebaceous Hyperplasia lesions. Non-thermal, cellular-specific NPS technology was featured at the opening Plenary Session, which highlights cutting-edge science and emerging therapies in dermatologic surgery. NPS technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent healthy, non-cellular tissue.
In prior studies, investigator assessments concluded that the NPS procedure met efficacy endpoints in 99.5 percent of Sebaceous Hyperplasia lesions and 82 percent of Seborrheic Keratosis lesions along with normal and expected skin recovery periods.”
Reference: Excerpt can be found in the technology portion of Practical Dermatology, 2019 in Review December 2019 feature.